BDTX bets on silevertinib's broad EGFR mutation reach and CNS activity, but with no approved products, upcoming 2026 data and partnerships are pivotal.

American Airlines Group Inc. has debt, weak margins, and tougher fuel/labor costs—lagging Delta/United and vulnerable to ...

Brain metastases remain a defining challenge in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer ...

The Australian Dollar is poised to end Friday’s session flat, even though an improvement in market mood drove the Greenback ...

Top insights from the latest market news from Friday, April 10, from The Motley Fool analysts on Team Rule Breakers and Team ...